Complete the activity and claim credit here: bit.ly/40dd3nc
0:00 - Introduction
0:58 - Background
4:57 - Diagnosis
8:17 - topical therapy
10:36 - Ruxolitinib
13:22 - Tapinarof
15:17 - Roflumilast
17:36 - Systemic therapy
20:41 - Dupilumab
23:38 - Tralokinumab
24:27 - Lebrikizumab
25:18 - Nemolizumab
26:08 - Abrocitinib
27:09 - Upadacitinib
28:00 - Selecting systemic therapy
29:14 - OX40 inhibitors
30:39 - Rocatinlimab
31:05 - Amlitelimab
32:14 - Key Takeaways
Explore the latest advancements in treating atopic dermatitis in children and adolescents with insights from Dr. Peter A. Lio and Dr. Linda F. Stein Gold. Atopic dermatitis affects up to 20% of children in the U.S., leading to symptoms like pruritus, pain, and sleep disturbances that can severely impact quality of life.
STATEMENT OF NEED
Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that impacts up to 20% of children in the United States (Silverberg et al, 2021). Children with atopic dermatitis experience a high symptom burden, including pruritus, pain, and sleep disturbances, which significantly impact quality of life. Recently, the therapeutic landscape for atopic dermatitis has expanded to include several new options for children (Chu et al, 2024; Davis et al, 2024). Nonsteroidal topicals, topical and oral JAK inhibitors, and anti-IL-4 receptor alpha and anti-IL-13 monoclonal antibodies, are now available to patients. Others, including therapies targeting the OX40 pathway, are under late-stage investigation (Tsuji et al, 2023). As new therapies emerge, it is crucial for members of the interdisciplinary care team to learn about these options that can optimize outcomes for patients. In this activity, Dr. Peter A. Lio, Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, and Dr. Linda F. Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology at Henry Ford Health, provide insights into best practices and emerging evidence in the treatment of atopic dermatitis in children and adolescents.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Appraise clinical features that can inform the differential diagnosis of AD in children and adolescents
- Evaluate the efficacy and safety of novel and emerging therapies for AD in children and adolescents
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Peter A. Lio, MD, discloses that he has served on a speaker's bureau for AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L'Oreal, MyOR Diagnostics, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, and Verrica; that he has served on an advisory board or panel for AbbVie, Alphyn Biologics, Almirall, Amyris, Arcutis, Bristol Myers Squibb, Codex Labs, Concerto Biosci, Dermavant, Eli Lilly, Galderma, Hyphens Pharma, Incyte, Janssen, La Roche-Posay/L'Oreal, LEO Pharma, Micreos, MyOR Diagnostics, Pathos Therapeutics, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzye, Skinfix, Soteri Skin, Suneco Technologies, UCB, Verdant Scientific, Verrica, and Yobee Care; that he is a stock/shareholder with Alphyn Biologics, Codex Labs, Concerto Biosci, Soteri Skin, Suneco Technologies, Verdant Scientific, and Yobee Care; and that he has received other financial or material support (royalties, patents, etc.) from Theraplex.
Linda F. Stein Gold, MD, discloses that she has served on a speaker's bureau for AbbVie, Amgen, Arcutis, Dermavant, Incyte, Leo, Lilly, Pfizer, Regeneron, and Sanofi; that she has served on an advisory board or panel for AbbVie, Amgen, Arcutis, Dermavant, Incyte, Leo, Lilly, Pfizer, Regeneron, and Sanofi; that she has served as a consultant for AbbVie, Amgen, Arcutis, Dermavant, Incyte, Leo, Lilly, Pfizer, Regeneron, and Sanofi; and that she has received grants/research support from AbbVie, Amgen, Arcutis, Dermavant, Incyte, Leo, Lilly, Pfizer, Regeneron, and Sanofi.
i3 Health has mitigated all relevant financial relationships.
#AtopicDermatitis #MonoclonalAntibodies #EczemaTreatment #PediatricDermatology #SkinHealth #JAKInhibitors #DermatologyCare #ChildHealth #SkinCareTips #InflammatorySkinDisease